ChitogenX Inc. (CHGX.CN)
CAD 0.01
(0.0%)
CAD 0.01
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 3.27 Million CAD | 38.76% |
| 2022 | 2.36 Million CAD | -50.52% |
| 2021 | 4.77 Million CAD | 3.49% |
| 2020 | 4.61 Million CAD | 125.23% |
| 2019 | 2.04 Million CAD | 158.82% |
| 2018 | 791.65 Thousand CAD | 30.37% |
| 2017 | 607.23 Thousand CAD | 0.0% |
| 2016 | - CAD | 0.0% |
| 2015 | - CAD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 115 Thousand CAD | 0.0% |
| 2024 Q1 | 115 Thousand CAD | -96.49% |
| 2023 Q1 | 2.42 Million CAD | 2.45% |
| 2023 FY | 3.27 Million CAD | 38.76% |
| 2023 Q2 | 2.49 Million CAD | 2.89% |
| 2023 Q4 | 3.27 Million CAD | 27.64% |
| 2023 Q3 | 2.56 Million CAD | 3.13% |
| 2022 Q2 | 2.53 Million CAD | -48.36% |
| 2022 Q4 | 2.36 Million CAD | -9.81% |
| 2022 FY | 2.36 Million CAD | -50.52% |
| 2022 Q1 | 4.91 Million CAD | 2.91% |
| 2022 Q3 | 2.62 Million CAD | 3.23% |
| 2021 Q1 | 2.19 Million CAD | -52.44% |
| 2021 FY | 4.77 Million CAD | 3.49% |
| 2021 Q4 | 4.77 Million CAD | 2.8% |
| 2021 Q3 | 4.64 Million CAD | 2.83% |
| 2021 Q2 | 4.51 Million CAD | 105.83% |
| 2020 Q3 | 2.72 Million CAD | -4.32% |
| 2020 Q1 | 2.69 Million CAD | 31.28% |
| 2020 Q2 | 2.84 Million CAD | 5.8% |
| 2020 Q4 | 4.61 Million CAD | 69.48% |
| 2020 FY | 4.61 Million CAD | 125.23% |
| 2019 Q1 | 716 Thousand CAD | -9.56% |
| 2019 Q3 | 1.38 Million CAD | 85.45% |
| 2019 Q4 | 2.04 Million CAD | 47.52% |
| 2019 Q2 | 749 Thousand CAD | 4.61% |
| 2019 FY | 2.04 Million CAD | 158.82% |
| 2018 Q3 | 135.4 Thousand CAD | 0.0% |
| 2018 Q1 | - CAD | -100.0% |
| 2018 FY | 791.65 Thousand CAD | 30.37% |
| 2018 Q4 | 791.65 Thousand CAD | 484.66% |
| 2018 Q2 | - CAD | 0.0% |
| 2017 Q2 | 782.43 Thousand CAD | 46.89% |
| 2017 Q1 | 532.68 Thousand CAD | 0.0% |
| 2017 FY | 607.23 Thousand CAD | 0.0% |
| 2017 Q4 | 607.23 Thousand CAD | 4.27% |
| 2017 Q3 | 582.38 Thousand CAD | -25.57% |
| 2016 Q4 | - CAD | 0.0% |
| 2016 Q3 | - CAD | 0.0% |
| 2016 Q1 | - CAD | 0.0% |
| 2016 FY | - CAD | 0.0% |
| 2016 Q2 | - CAD | 0.0% |
| 2015 Q4 | - CAD | 0.0% |
| 2015 FY | - CAD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | - CAD | -Infinity% |
| Asep Medical Holdings Inc | - CAD | -Infinity% |
| BetterLife Pharma Inc. | 245.23 Thousand CAD | -1237.09% |
| BioVaxys Technology Corp. | - CAD | -Infinity% |
| Rapid Dose Therapeutics Corp. | 2.12 Million CAD | -54.315% |
| Defence Therapeutics Inc. | 7871.00 CAD | -41559.255% |
| Entheon Biomedical Corp. | - CAD | -Infinity% |
| Gemina Laboratories Ltd. | 205.98 Thousand CAD | -1491.887% |
| Glow Lifetech Corp. | - CAD | -Infinity% |
| Lexston Life Sciences Corp. | - CAD | -Infinity% |
| Pharmala Biotech Holdings Inc. | - CAD | -Infinity% |
| Doseology Sciences Inc. | - CAD | -Infinity% |
| MYND Life Sciences Inc. | - CAD | -Infinity% |
| Nova Mentis Life Science Corp. | - CAD | -Infinity% |
| PharmaTher Holdings Ltd. | - CAD | -Infinity% |
| PreveCeutical Medical Inc. | - CAD | -Infinity% |
| Telescope Innovations Corp. | - CAD | -Infinity% |